A Randomized, Open-label, Single-dose, 2-sequence, Two-period, Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers
Latest Information Update: 30 Jan 2026
At a glance
- Drugs Padoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 30 Jan 2026 New trial record